Asston Pharmaceuticals Limited - Laporan Laba Rugi (TTM)

Asston Pharmaceuticals Limited
IN ˙ BSE
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Asston Pharmaceuticals Limited menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2021
03-31
2022
03-31
2023
03-31
2024
03-31
2025
03-31
Revenue 80 96 65 156 250
Change (%) 19.47 -31.89 138.39 60.65
% of Revenue 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 53 77 33 98 141
Change (%) 44.47 -56.35 191.23 45.00
% of Revenue 66.11 79.95 51.23 62.58 56.49
Gross Operating Profit 27 19 32 58 109
Change (%) -29.30 65.66 82.90 86.82
% of Revenue 33.89 20.05 48.77 37.42 43.51
SG&A 5 6 6 9 15
Change (%) 13.02 -4.05 48.57 70.51
% of Revenue 6.81 6.44 9.07 5.65 6.00
R&D
Change (%)
% of Revenue
OpEx 78 100 51 123 187
Change (%) 27.88 -49.23 144.08 51.66
% of Revenue 96.97 103.79 77.37 79.21 74.78
Operating Income 2 -4 15 32 63
Change (%) -249.37 -506.85 118.94 94.90
% of Revenue 3.03 -3.79 22.63 20.79 25.22
Interest Expense -1 -4 -7 -9 -8
Change (%) 425.89 58.89 33.39 -11.46
% of Revenue -1.01 -4.43 -10.33 -5.78 -3.19
Net Income 1 1 11 14 43
Change (%) 20.70 855.33 28.74 217.95
% of Revenue 1.14 1.15 16.16 8.73 17.27

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista